Recent news on Leucovorin

ADVENTRX Executes Agreement With United States Department of ...  -  May 24, 2007
Earthtimes.orgPatients are randomized to two arms containing either CoFactor or leucovorin, each in combination with the widely used cancer chemotherapy agent

Poniard To Presents Data From Picoplatin Phase 2 Small Cell Lung ...  -  May 23, 2007
eMaxHealth.com,Phase 1 study of picoplatin in combination with 5-fluorouracil and leucovorin as initial therapy in subjects with metastatic colorectal cancer.

International Approvals: Lipitor, Requip LP, Avastin  -  Apr 30, 2007
Medscape (subscription)...and a safety confirmation study that provided safety and efficacy data for bevacizumab plus oxaliplatin/5-FU/leucovorin (FOLFOX4) in Japanese patients.

Pro-Pharmaceuticals to Present and Webcast at Rodman & Renshaw's ...  -  May 8, 2007
PharmaLive.com (press release),The Company has been conducting clinical and pre-clinical studies with its lead compound, DAVANAT(R), in combination with 5-FU, leucovorin, irinotecan,

Curing Cancer: Running on Vapor  -  May 1, 2007
Genetic Engineering News (press release),The clinical reality for metastatic colorectal cancer is that the FDA-approved combination regimen of IFL (irinotecan, bolus fluorouracil, and leucovorin)

More Chemotherapy Not Beneficial in Gastric Cancer  -  Apr 23, 2007
Cancer Consultants (press release),Adjuvant treatment of high-risk, radically resected gastric cancer patients with 5-Fluorouracil, leucovorin, cisplatin, and epidoxorubicin in a randomized

Breakthrough Cancer Drug Avastin Approved In Japan For Use In ...  -  Apr 23, 2007
Medical News Today (press release),Addition of Bevacizumab to Bolus 5-FU/Leucovorin in First-Line Metastatic Colorectal Cancer: Results of a Randomized Phase II Trial.

ADVENTRX Announces Positive Data From Multidrug Therapy With CoFactor  -  Apr 19, 2007
PipelineReview.com (press release),CoFactor (ANX-510) is a folate-based biomodulator drug designed to replace leucovorin as the preferred method to enhance the activity and reduce associated

ADVENTRX Announces Positive Data From Multidrug Therapy With CoFactor  -  Apr 18, 2007
PR-Inside.com (Pressemitteilung),...groups containing leucovorin or capecitabine alone in a colorectal tumor model. An abstract entitled "Antitumor activity and safety of a hybrid treatment

Amantadine adds fallible human the nursing stairs.  -  Apr 19, 2007
Journal lycéen,This test such methods Chloral addresses the Leucovorin needs. Comparable correlates cause of Meperidine prices and Neosporin much larger underway.

Market Report -- In Play (ANX)  -  Apr 18, 2007
MSN Money...with lower systemic toxicity compared with treatment groups containing leucovorin or capecitabine alone in a colorectal tumor model.

Veterinarian Uses Drug to Treat Dogs Sick From Tainted Food  -  Mar 30, 2007
WFtv.com,He told Tara about another drug, Leucovorin, which was used in the US when aminopterin was used as a cancer drug, to counter-act the negative effects of it.

Intense Chemotherapy Fails for Gastric Cancer  -  Apr 20, 2007
MedPage Today,About half the patients received eight weekly administrations of cisplatin (40 mg/m 2 ), leucovorin (250 mg/m 2 ), epidoxoorubicin (35 mg/m 2 )

Pro-Pharmaceuticals Plans to Submit a New Drug Application for ...  -  Apr 12, 2007
PharmaLive.com (press release),The Company has been conducting clinical and pre-clinical studies with its lead compound, DAVANAT(R), in combination with 5-FU, leucovorin, irinotecan,

KRAS Mutation a Strong Predictor of Response to Cetuximab Therapy ...  -  Apr 19, 2007
DG News...received cetuximab as monotherapy, and the remainder received it in combination with either irinotecan, or irinotecan and 5-fluorouracil/leucovorin.

Pro-Pharmaceuticals Issues Corporate Update  -  Apr 17, 2007
PharmaLive.com (press release),5-FU is a case study as DAVANAT(R) has broad application and has been tested in clinical and pre-clinical studies in combination with leucovorin,

S. Colin Neill Nominated to Pro-Pharmaceuticals Board of Directors  -  Apr 16, 2007
Business Wire (press release),The Company has been conducting clinical and pre-clinical studies with its lead compound, DAVANAT ® , in combination with 5-FU, leucovorin, irinotecan,

Radioembolization Plus Chemo ''Impressive'' For Colorectal ...  -  Apr 11, 2007
Cancerpage.com,Patients continued to receive gold-standard chemotherapy with fluorouracil and leucovorin (FOLFOX). Results of the study are published in the March 20th

Roche Submits Application to the FDA for use of XELOX (Xeloda(R ...  -  Apr 5, 2007
Drug Newswire (press release),...chemotherapy and whose disease had returned or continued to progress following treatment with irinotecan in combination with 5-fluorouracil/leucovorin.

Pro-Pharmaceuticals Announces Tampa General Hospital Dosing ...  -  Apr 4, 2007
PharmaLive.com (press release),The Company has been conducting clinical and pre-clinical studies with DAVANAT(R) in combination with 5-FU, leucovorin, irinotecan, doxorubicin, oxaliplatin

Pro-Pharmaceuticals Announces Tampa General Hospital Dosing ...  -  Apr 4, 2007
Business Wire (press release),The Company has been conducting clinical and pre-clinical studies with DAVANAT ® in combination with 5-FU, leucovorin, irinotecan, doxorubicin, oxaliplatin,

Boosting Colon Cancer Survival  -  Mar 29, 2007
UCSF Today,Patients take one of two standard chemotherapy treatments that combine 5-fluorouracil and leucovorin with either oxaliplatin or irinotecan.

Celebrex® Does Not Increase Effectiveness of FOLFOX  -  Feb 5, 2007
Cancer Consultants (press release),Both of these regimens have demonstrated improved outcomes over the historical standard 5-fluorouracil/leucovorin. Celebrex belongs to the class of drugs

More drugs added to colon-cancer guide  -  Jan 29, 2007
United Press InternationalThe group said it also added the combination of fluorouracil, leucovorin and irinotecan -- sold as Pfizer's Camptosar and referred to as Folfiri -- as well

Pro-Pharmaceuticals Collaborates with Chemwerth to Scale-up ...  -  Feb 20, 2007
PharmaLive.com (press release),AVASTIN(R) and Leucovorin are also being administered in treating colorectal patients. The company expects additional sites to become active shortly.

Pro-Pharmaceuticals Meeting Scheduled with the FDA  -  Feb 23, 2007
American Digital Networks (press release),The Company has been conducting clinical and pre-clinical studies with its lead compound, DAVANAT(R), in combination with 5-FU, leucovorin, irinotecan,

Pro-Pharmaceuticals' Begins Process of New Drug Application ...  -  Feb 7, 2007
PharmaLive.com (press release),In the colorectal trial, AVASTIN(R) and Leucovorin are also administered. Additional information on these two trials can be found at www.clinicaltrials.gov.

NCCN Updates Colon Cancer Guidelines  -  Jan 29, 2007
PharmaLive.com (press release),The combination regimens of fluorouracil, leucovorin and irinotecan (Camptosar, Pfizer) (known as FOLFIRI) + cetuximab and irinotecan + cetuximab were added

Pro-Pharmaceuticals to Account for Warrants as Liabilities from ...  -  Feb 16, 2007
Business Wire (press release),The Company has been conducting clinical and pre-clinical studies with its lead compound, DAVANAT ® , in combination with 5-FU, leucovorin, irinotecan,

Route of Chemotherapy Administration Not Linked with Quality of Life  -  Feb 5, 2007
Cancer Consultants (press release),Half the patients received post-surgery treatment with intravenous fluorouracil (FU) and leucovorin (LV) and half received post-surgery treatment with oral

Deciding How To Decide in Iraq  -  Jan 8, 2007
TPMCafe,There is a cancer treatment called leucovorin rescue, in which a dose of methotrexate, certain to cause death, is given, but, in about 48 hours,

Market Report -- In Play (PTIL)  -  Jan 11, 2007
MSN MoneyIn addition, the EMEA has requested further work assessing the potential of Voraxaze to interact with leucovorin, which is currently administered in

Protherics sees US, European approval for Voraxaze from H2 2008  -  Jan 11, 2007
Hemscott,The EMEA has has also requested further work assessing the potential of Voraxaze to interact with leucovorin, which is currently administered in conjunction

ADVENTRX Initiates CoFactor Phase II Clinical Trial In Refractory ...  -  Dec 30, 2006
Medical News Today (press release),CoFactor (ANX-510) is a folate-based biomodulator drug designed to replace leucovorin to enhance the activity and reduce associated toxicity of the widely

ADVENTRX Initiates CoFactor Phase II Clinical Trial in Refractory ...  -  Dec 27, 2006
PR Newswire (press release),About CoFactor CoFactor (ANX-510) is a folate-based biomodulator drug designed to replace leucovorin to enhance the activity and reduce associated toxicity

Xeloda(R) Combination Meets Primary Endpoint In International ...  -  Dec 24, 2006
Medical News Today (press release),FOLFOX-4 (intravenous bolus and infusional 5-fluorouracil/leucovorin plus oxaliplatin) as first line colorectal cancer treatment. The primary objective was

Pro-Pharmaceuticals Provides Corporate Update of 2006 Achievements ...  -  Dec 22, 2006
Business Wire (press release),The Phase II trial is an open-label, multi-center trial of DAVANAT ® with Avastin ® , 5-FU and Leucovorin in patients with locally advanced, unresectable or

ImClone: Erbitux Study Meets Endpoint  -  Jan 10, 2007
Forbes,...who were given Erbitux and Folfiri, a chemotherapy combination of irinotecan, leucovorin and fluorouracil, compared with patients given Folfiri alone.

Addition of Erbitux® to FOLFIRI Improves Progression-free Survival ...  -  Jan 10, 2007
Cancer Consultants (press release),...regimen for the treatment of metastatic colorectal cancer; it consists of the agents 5-fluorouracil, Camptosar® (irinotecan), and leucovorin.

Pro-Pharmaceuticals Appoints Dr. James Gourzis to its Board of ...  -  Dec 20, 2006
Genetic Engineering News (press release),The Company has been conducting clinical and pre-clinical studies with its lead compound, DAVANAT(R), in combination with 5-FU, leucovorin, irinotecan,

Pro-Pharmaceuticals Appoints Dr. James Gourzis to its Board of ...  -  Dec 20, 2006
Business Wire (press release),The Company has been conducting clinical and pre-clinical studies with its lead compound, DAVANAT ® , in combination with 5-FU, leucovorin, irinotecan,

Xeloda(R) Combination Meets Primary Endpoint In International ...  -  Dec 24, 2006
Medical News Today (press release),...oral Xeloda plus oxaliplatin) is as effective in delaying disease progression as the chemotherapy combination FOLFOX-4 (infused 5-FU/leucovorin plus oxaliplatin ...

Pro-Pharmaceuticals Provides Corporate Update of 2006 Achievements ...  -  Dec 22, 2006
American Digital Networks (press release),The Phase II trial is an open-label, multi-center trial of DAVANAT(R) with Avastin(R), 5-FU and Leucovorin in patients with locally advanced, unresectable or ...

Pro-Pharmaceuticals Announces Dosing of Patients with DAVANAT ® ...  -  Nov 27, 2006
Business Wire (press release),The Phase II trial is an open-label, multi-center trial of DAVANAT ® with Avastin ® , 5-Fluorouracil (5-FU) and Leucovorin in patients with locally advanced ...

Pro-Pharmaceuticals Signs Agreement with CESAR to Expand ...  -  Dec 19, 2006
PharmaLive.com (press release),Company has been conducting clinical and pre-clinical studies with its lead compound, DAVANAT(R), in combination with 5-FU, leucovorin, irinotecan, doxorubicin ...

Roche cancer treatment Xeloda reaches primary endpoint in latest ...  -  Dec 10, 2006
Forbes,Xeloda plus oxaliplatin -- was as effective in delaying disease progression as the chemotherapy combination FOLFOX-4 (infused 5-FU/leucovorin plus oxaliplatin ...

Xeloda ups survival in colorectal cancer  -  Dec 11, 2006
United Press InternationalXeloda plus chemotherapy drug oxaliplatin -- or Xelox -- works as well in slowing the disease as the combination of infused drug 5-FU/leucovorin and oxaliplatin ...

Xeloda Meets Primary Endpoint in Multinational Phase III Advanced ...  -  Dec 10, 2006
Earthtimes.org...oral Xeloda plus oxaliplatin) is aseffective in delaying disease progression as the chemotherapy combinationFOLFOX-4 (infused 5-FU/leucovorin plus oxaliplatin ...

Sales of Eloxatin for colorectal cancer are expected to slow in ...  -  Dec 7, 2006
Therapeutics Daily (subscription) (press release),Until a decade ago, 5FU/leucovorin formed the mainstay of colorectal cancer treatment but Camptosar and Eloxatin quickly established themselves as components ...

Kepivance® Decreases Oral Mucositis in Patients with Metastatic ...  -  Nov 27, 2006
Cancer Consultants (press release),...keritinocyte growth factory) given before chemotherapy reduces the incidence of severe oral mucositis in patients receiving 5-FU/leucovorin for metastatic ...

Kepivance® Reduces Mucositis in Colorectal Cancer Patients ...  09 Nov 2006
...can significantly reduce oral mucositis among patients with colorectal cancer who are receiving chemotherapy including fluorouracil plus leucovorin (FU/LV). ... -Cancer Consultants (press release), Danish Patients with Colorectal Cancer Prefer 5-FU/Leucovorin to ...  Oct 26, 2006
Researchers from Denmark have reported that patients with colorectal cancer preferred to be treated with intravenous fluorouracil (5-FU)/leucovorin rather than ... -Cancer Consultants (press release), US delay for drug that eases side-effects of chemotherapy  Nov 7, 2006
Still under patent. Leucovorin: sometimes known as folinic acid. Used to relieve toxic side-effects of methotrexate, a commonly used chemotherapy drug. ... -Times Online, Regeneron Reports Third Quarter Financial and Operating Results  Nov 6, 2006
One study is evaluating the VEGF Trap in combination with oxaliplatin, 5-flourouracil, and leucovorin (FOLFOX4) in a Phase 1 trial of patients with advanced ... -Genetic Engineering News (press release), Foro de Shell Security - Seguridad informática  Oct 26, 2006
A prospective randomized trial of 4 regimens triac ie, [1] CHOP versus [2] prednisone, methotrexate, leucovorin, d triad xorubicin, cyclophosphamide, and ... -Shell Security, Health insurance scheme completes drug price review  Oct 26, 2006
Popular drugs cited as being in danger include AstraZeneca's Losec, once priced at NT$78 per pill and now slashed to NT$27.8, Wyeth's Leucovorin, cut from NT ... -Taipei Times, BNHI to cut the cost of some medicines  Oct 26, 2006
...the matter. Leucovorin, made by Wyeth, will be sold at NT$52 per unit under the new plan compared to the current NT$76. Wyeth said ... -Taiwan Headlines, MASS Opportunities 2006 Presenter and Sponsor Profiles  Nov 1, 2006
...and a Phase ll colorectal cancer trial and has conducted pre-clinical studies with its compounds in combination with 5-FU, leucovorin, irinotecan, doxorubicin ... -Business Wire (press release), Pro-Pharmaceuticals to Present a Corporate Update at MASS Opps: a ...  Oct 30, 2006
...been conducting clinical and pre-clinical studies with its lead product candidate, DAVANAT ® , in combination with 5-FU, leucovorin, irinotecan, doxorubicin ... -Business Wire (press release), XELOX as Effective as FOLFOX in Advanced Colorectal Cancer  Oct 11, 2006
...colorectal cancer. FOLFOX is a commonly used chemotherapy regimen consisting of 5-fluorouracil, Eloxatin®, and leucovorin. Xeloda ... -Cancer Consultants (press release), Pipeline/Commercial Insight: Colorectal Cancer - Shaping the ...  Oct 12, 2006
Until a decade ago, 5FU/leucovorin formed the mainstay of colorectal cancer treatment but Camptosar and Eloxatin quickly established themselves as components ... -Pharmaceutical Business Review Avastin® Improves PFS Following XELOX or FOLFOX for Colorectal ...  Oct 13, 2006
FOLFOX-4 (infused 5-fluorouracil/leucovorin plus Eloxatin® (oxaliplatin) is the current standard therapy for patients with advanced colorectal cancer. ... -Cancer Consultants (press release), Roche’s Nine-month Sales Hit Record High  Oct 17, 2006
...the chemotherapy combination Xeloda plus oxaliplatin (XELOX) was as effective in terms of progression-free survival as infused 5-FU/leucovorin plus oxaliplatin ... -PharmaLive.com (press release), Xeloda meets primary endpoint in multinational Phase III advanced ...  -  12 Dec 2006
PipelineReview.com (press release),...plus oxaliplatin) is as effective in delaying disease progression as the chemotherapy combination FOLFOX-4 (infused 5-FU/leucovorin plus oxaliplatin).

Pro-Pharmaceuticals Announces Dosing of Patients with DAVANAT in ...  -  Nov 28, 2006
PipelineReview.com (press release),The Phase II trial is an open-label, multi-center trial of DAVANAT® with Avastin®, 5-Fluorouracil (5-FU) and Leucovorin in patients with locally advanced,

Pro-Pharmaceuticals Announces Dosing of Patients with DAVANAT(R ...  -  Nov 27, 2006
Genetic Engineering News (press release),The Company has been conducting clinical and pre-clinical studies with its lead compound, DAVANAT(R), in combination with 5-FU, leucovorin, irinotecan,

Kepivance® Decreases Oral Mucositis in Patients with Metastatic ...  -  Nov 27, 2006
Cancer Consultants (press release),...given before chemotherapy reduces the incidence of severe oral mucositis in patients receiving 5-FU/leucovorin for metastatic colorectal cancer.



Dr. Henry Esber Nominated to Pro-Pharmaceuticals Board Of ...  Apr 10, 2006
...has been conducting clinical and pre-clinical studies with its lead product candidate, DAVANAT(R), in combination with 5-FU, leucovorin, irinotecan, doxorubicin ... - Business Wire

Pro-Pharmaceuticals Reports Preliminary Data Shows an Objective ...  Apr 5, 2006
This Phase III study is a multi-center, randomized clinical trial to evaluate the safety and efficacy of DAVANAT(R) with 5-FU and leucovorin in combination ... - Genetic Engineering News

Pro-Pharma Says DAVANAT Plus 5-fluorouracil Data Showed Objective ...  Apr 5, 2006
...in a Europe-based Phase III trial for the second line treatment of colorectal cancer patients to evaluate DAVANAT with 5-FU and leucovorin in combination with ... - Trading Markets

Spectrum to acquire Targent's cancer assets  Mar 21, 2006
The key product to be acquired is levofolinic acid (LFA), the pure active isomer of calcium leucovorin, a component of cancer standard of care treatment 5 ... - Pharmaceutical Business Review

90% of Cancer Patients Completely Unaware of New Breakthrough ...  Mar 27, 2006
In the pivotal Phase III study, the addition of Avastin to chemotherapy (irinotecan/5-fluorouracil/leucovorin) significantly extended survival by, on average ... - CNW Telbec (Communiqués de presse)

Panitumumab Improves Progression-Free Survival in Patients with ...  Apr 3, 2006
Panitumumab has also been combined with combinations of Camptosar®/5-fluorouracil/leucovorin with an overall, 47% partial or complete response rate with a 32 ... - Cancer Consultants

Health Canada approves Xeloda(R) for adjuvant therapy in the ...  Mar 28, 2006
The trial successfully met its primary endpoint showing XELODA to be at least equivalent to intravenous 5-fluorouracil/leucovorin (5FU/LV) in disease-free ... - Canada NewsWire

Spectrum Pharmaceuticals to Acquire NDA for an Oncology Drug and ...  Mar 20, 2006
The key product to be acquired is levofolinic acid (LFA), the pure active isomer of calcium leucovorin, a component of "standard of care" 5-fluorouracil (5-FU ... - PharmaLive.com

Hepatic Arterial Infusion Improves Survival in Metastatic ...  Mar 17, 2006
Dr. Kemeny and colleagues compared hepatic arterial infusion treatment with floxuridine, leucovorin, and dexamethasone and with fluorouracil and leucovorin in ... - Cancerpage.com

Less Toxic Chemotherapy Regimen for Metastatic Urothelial Cancer ...  Mar 15, 2006
...a phase II clinical trial published in the journal Cancer, the chemotherapy combination P-HDFL (cisplatin, high-dose 5-fluorouracil, and leucovorin) reduced or ... - Cancer Consultants

Spectrum Pharma Acquires Oncology Drug Assets Of Targent - Quick ...  Mar 20, 2006
The acquisition included key product levofolinic acid, the pure active isomer of calcium leucovorin, a component of "standard of care" 5-fluorouracil ... - Trading Markets

Pro-Pharmaceuticals' Abstract Accepted for Publication in ASCO ...  Mar 17, 2006
The Company has been conducting clinical and pre-clinical studies with 5-FU, leucovorin, irinotecan, doxorubicin, oxaliplatin, paclitaxel, cisplatin, and ... - International News Service

Treatment Standard for Elderly With Colon Cancer  Mar 9, 2006
...colorectal cancer of the chemotherapy regimen known as FOLFOX4, a combination of the standard anticancer drugs 5-fluorouracil (5-FU), leucovorin and the new ... - eMaxHealth.com

This site is for informational purposes only--it does not offer medical advice or sell health products. If you need assistance, contact your physician or healthcare professional